A New Treatment After CAR T-Cell Therapy for Multiple Myeloma

This trial is testing whether talquetamab—a new type of cancer-fighting medication—works well as a follow-up treatment after you've received CAR T-cell therapy (a type of immunotherapy) for multiple myeloma. Researchers want to see if this medication can help keep your cancer under control and prevent it from coming back. All participants in this study will have already received CAR T-cell therapy before joining.

Multiple myeloma often comes back after initial treatments, and doctors are looking for better ways to prevent relapse after CAR T-cell therapy. This trial tests whether this medication could be an effective next step to help keep the disease from progressing.